Last updated: February 20, 2026
What is NDC 68001-0533?
NDC 68001-0533 is a drug marketed under the name Forteo (teriparatide), used for osteoporosis treatment. It is a recombinant form of parathyroid hormone administered via subcutaneous injection. As a biologic, Forteo is prescribed for high-risk osteoporosis patients to reduce fracture incidence.
Market Overview
Current Market Size
The global osteoporosis drug market was valued at approximately $9.1 billion in 2022. Forteo accounts for an estimated 5% of this market, roughly $455 million.
Patient Demographics
- Target Population: Postmenopausal women, men age 50+, patients with glucocorticoid-induced osteoporosis.
- Market Penetration: Estimated at 12-15% among eligible patients, based on recent prescription data.
- Market Growth Rate: CAGR of around 4% projected through 2027 (source: IQVIA data).
Competition Landscape
Key competitors include:
- Denosumab (Prolia/Xgeva)
- Romosozumab (Evenity)
- Bisphosphonates (e.g., alendronate, zoledronic acid)
Forteo's market share is challenged by newer agents with less administration frequency and different mechanism of action but retains appeal for specific patient subsets.
Regulatory and Reimbursement Environment
- FDA Approval Date: April 2002.
- Insurance Coverage: Widely covered, but cost considerations influence prescribing patterns.
- Reimbursement Trends: Shifting toward value-based models, impacting biologic drug pricing.
Price Trends and Projections
Historical Pricing Data
- Average Wholesale Price (AWP) (2022): Approximately $4,100 per 28-day supply.
- Average Sales Price (ASP): Around $3,950 per 28-day kit.
- Reimbursement Price (Medicare): Approximately $3,850.
Prices for biologics like Forteo have exhibited a stable trend with minor fluctuations due to market factors.
Key Factors Influencing Price
- Patent Status: Forteo’s patent expired in 2019, opening pathways for biosimilar development.
- Biosimilar Entry: Potential biosimilar approval could prompt significant price reductions.
- Manufacturing Costs: Biosimilars are expected to reduce prices by approximately 20-40% relative to originator.
- Market Penetration of Biosimilars: Delayed due to regulatory hurdles, but imminent — potential biosimilar launches projected for 2024-2025.
Future Price Projections (2023-2028)
| Year |
Estimated Price Range (per 28-day supply) |
Notes |
| 2023 |
$3,900 - $4,100 |
Market stabilization |
| 2024 |
$3,200 - $3,600 |
Biosimilar approval impact begins |
| 2025 |
$2,800 - $3,200 |
Biosimilar market penetration increases |
| 2026 |
$2,400 - $2,800 |
Institutional procurement shifts |
| 2027 |
$2,200 - $2,500 |
Price adjustments for market competitiveness |
Market Drivers for Price Decline
- Biosimilar competition undercuts originator pricing.
- Health policies favoring cost savings.
- Increased use of less expensive alternatives, including oral bisphosphonates or novel agents.
Risks Impacting Pricing and Market Share
- Regulatory Delays: Biosimilar approvals may be delayed beyond 2024.
- Physician Acceptance: Slower adoption of biosimilars due to prescriber comfort with originator biologic.
- Patent Litigation: Potential legal actions could extend Forteo’s exclusivity.
Strategic Implications
- Companies holding Forteo’s patent (Eli Lilly) face erosion of revenue due to biosimilar competition.
- Investment decisions could favor biosimilar entrants or alternative therapies.
- Payers may limit coverage or impose step therapy protocols to control costs.
Summary of Key Data
| Aspect |
Details |
| Current market size |
~$455 million (Forteo's share) |
| Price (2022) |
~$4,000 per 28-day supply |
| Patent expiry |
2019 |
| Biosimilar approval forecast |
2024-2025 |
| Future price estimate (2024) |
~$3,200 - $3,600 |
| Market growth rate |
4% CAGR (2022-2027) |
Key Takeaways
- Forteo faces ongoing price erosion primarily driven by biosimilar entry.
- The biologic's market share will decline over the next 2-3 years.
- Pricing will likely settle near $2,200-$2,500 per 28-day supply by 2027.
- Market dynamics will be influenced by regulatory developments and prescriber acceptance of biosimilars.
- Continued growth in osteoporosis treatment options could further diversify the market.
FAQs
Q1: When are biosimilars for Forteo expected to enter the market?
A1: Biosimilar approvals are forecasted for 2024-2025, with first launches potentially in 2024.
Q2: How will biosimilar entry affect Forteo's market share?
A2: Significant decline, potentially reducing originator sales by up to 50% within two years post-launch.
Q3: What are the primary factors determining future biologic pricing?
A3: Biosimilar competition, regulatory environment, healthcare reimbursement policies, and manufacturing costs.
Q4: How does Forteo compare price-wise to other osteoporosis therapies?
A4: It is priced higher than oral bisphosphonates but remains competitive with other biologics like denosumab.
Q5: What barriers exist for biosimilar adoption?
A5: Prescriber familiarity, patent litigation, and regulatory approval processes.
Sources
[1] IQVIA. (2022). Global prescription drug market analysis.
[2] FDA. (2002). Forteo (teriparatide) approval announcement.
[3] MedTech Insight. (2023). Biosimilar pipeline and approval status.
[4] Medicare Pricing Data. (2023). Reimbursement trends for biologics.
[5] EvaluatePharma. (2022). Biologic drug pricing and market forecasts.
